The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Delfini Lisa since 2023.
This trader's CIK number is 1873253.
At the time of last reporting, Delfini Lisa was the Chief Financial Officer of Trevi Therapeutics, Inc.. (stock ticker symbol TRVI).
Also see all insider trading activities at Trevi Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | TRVI | 0 | $0 | 0 | $0 | 6,000 | $3,066 |
| 2024 | TRVI | 0 | $0 | 4,350 | $11,484 | 16,043 | $8,197 |
| 2023 | TRVI | 0 | $0 | 14,243 | $33,467 | 45,832 | $23,416 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-01-07 | TRVI | Option Ex | 1,000 | .51 | 511 |
| 2025-01-08 | TRVI | Option Ex | 5,000 | .51 | 2,555 |
| 2024-05-22 | TRVI | Option Ex | 16,043 | .51 | 8,197 |
| 2024-05-22 | TRVI | Sale | 4,350 | 2.64 | 11,484 |
| 2023-10-11 | TRVI | Sale | 785 | 2.02 | 1,585 |
| 2023-10-11 | TRVI | Option Ex | 2,292 | .51 | 1,171 |
| 2023-09-11 | TRVI | Option Ex | 2,291 | .51 | 1,170 |
| 2023-09-11 | TRVI | Sale | 711 | 2.20 | 1,564 |
| 2023-08-11 | TRVI | Option Ex | 2,292 | .51 | 1,171 |
| 2023-08-11 | TRVI | Sale | 682 | 2.36 | 1,609 |
| 2023-07-11 | TRVI | Option Ex | 2,292 | .51 | 1,171 |
| 2023-07-11 | TRVI | Sale | 687 | 2.34 | 1,607 |
| 2023-06-12 | TRVI | Option Ex | 2,291 | .51 | 1,170 |
| 2023-06-12 | TRVI | Sale | 610 | 2.64 | 1,610 |
| 2023-05-11 | TRVI | Sale | 562 | 2.89 | 1,624 |
| 2023-05-11 | TRVI | Option Ex | 2,291 | .51 | 1,170 |
| 2023-04-11 | TRVI | Sale | 840 | 1.84 | 1,544 |
| 2023-04-11 | TRVI | Option Ex | 2,292 | .51 | 1,171 |
| 2023-03-13 | TRVI | Option Ex | 2,291 | .51 | 1,170 |
| 2023-03-13 | TRVI | Sale | 892 | 1.75 | 1,563 |
| 2023-02-13 | TRVI | Option Ex | 27,500 | .51 | 14,052 |
| 2023-02-13 | TRVI | Sale | 8,474 | 2.45 | 20,761 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Delfini Lisa (Chief Financial Officer of Trevi Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.